TY - JOUR
T1 - Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa
AU - ZHANG, Hongjie
AU - Rumschlag-Booms, Emily
AU - GUAN, Yifu
AU - Wang, Dong Ying
AU - Liu, Kang Lun
AU - Li, Wan Fei
AU - Nguyen, Van H.
AU - Cuong, Nguyen M.
AU - Soejarto, Djaja D.
AU - Fong, Harry H.S.
AU - Rong, Lijun
N1 - Publisher Copyright:
© 2017 The American Chemical Society and American Society of Pharmacognosy.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2017/6/23
Y1 - 2017/6/23
N2 - Justicia gendarussa, a medicinal plant collected in Vietnam, was identified as a potent anti-HIV-1 active lead from the evaluation of over 4500 plant extracts. Bioassay-guided separation of the extracts of the stems and roots of this plant led to the isolation of an anti-HIV arylnaphthalene lignan (ANL) glycoside, patentiflorin A (1). Evaluation of the compound against both the M-and T-Tropic HIV-1 isolates showed it to possess a significantly higher inhibition effect than the clinically used anti-HIV drug AZT. Patentiflorin A and two congeners were synthesized, de novo, as an efficient strategy for resupply as well as for further structural modification of the anti-HIV ANL glycosides in the search for drug leads. Subsequently, it was determined that the presence of a quinovopyranosyloxy group in the structure is likely essential to retain the high degree of anti-HIV activity of this type of compounds. Patentiflorin A was further investigated against the HIV-1 gene expression of the R/U5 and U5/gag transcripts, and the data showed that the compound acts as a potential inhibitor of HIV-1 reverse transcription. Importantly, the compound displayed potent inhibitory activity against drug-resistant HIV-1 isolates of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine). Thus, the ANL glycosides have the potential to be developed as novel anti-HIV drugs.
AB - Justicia gendarussa, a medicinal plant collected in Vietnam, was identified as a potent anti-HIV-1 active lead from the evaluation of over 4500 plant extracts. Bioassay-guided separation of the extracts of the stems and roots of this plant led to the isolation of an anti-HIV arylnaphthalene lignan (ANL) glycoside, patentiflorin A (1). Evaluation of the compound against both the M-and T-Tropic HIV-1 isolates showed it to possess a significantly higher inhibition effect than the clinically used anti-HIV drug AZT. Patentiflorin A and two congeners were synthesized, de novo, as an efficient strategy for resupply as well as for further structural modification of the anti-HIV ANL glycosides in the search for drug leads. Subsequently, it was determined that the presence of a quinovopyranosyloxy group in the structure is likely essential to retain the high degree of anti-HIV activity of this type of compounds. Patentiflorin A was further investigated against the HIV-1 gene expression of the R/U5 and U5/gag transcripts, and the data showed that the compound acts as a potential inhibitor of HIV-1 reverse transcription. Importantly, the compound displayed potent inhibitory activity against drug-resistant HIV-1 isolates of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine). Thus, the ANL glycosides have the potential to be developed as novel anti-HIV drugs.
UR - http://www.scopus.com/inward/record.url?scp=85021114930&partnerID=8YFLogxK
U2 - 10.1021/acs.jnatprod.7b00004
DO - 10.1021/acs.jnatprod.7b00004
M3 - Article
C2 - 28613071
AN - SCOPUS:85021114930
SN - 0163-3864
VL - 80
SP - 1798
EP - 1807
JO - Journal of Natural Products
JF - Journal of Natural Products
IS - 6
ER -